Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Irp Health Pty Ltd. currently has 1 pending office action in the Chemistry & Materials technology area. This single matter is assigned to 1 distinct examiner, reflecting a very specific and focused prosecution effort for the company's current filings. The activity is confined to 1 distinct art unit at the USPTO.
ZILBERING, ASSAF is the busiest examiner for the portfolio, currently managing 1 pending office action. Since there is only 1 pending office action in total, ZILBERING, ASSAF is responsible for the company's entire active workload. This concentration in 1 distinct art unit suggests that the company's current innovation is highly specialized within the chemistry sector.
The presence of 1 pending office action indicates a low volume of current correspondence with the patent office. ZILBERING, ASSAF oversees 1 pending office action, which constitutes the entirety of the company's active prosecution pipeline. This streamlined interaction allows the company to focus its resources on the specific feedback provided by a single examiner within a single technical discipline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZILBERING, ASSAF | 1 | 35.3% | +27.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18991095 | BERBERINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE | ZILBERING, ASSAF | — |
| Art Unit | Apps |
|---|---|
| 1792 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18991095 | BERBERINE ALKALOID FORMULATIONS IN THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASE | ZILBERING, ASSAF | 1792 | §103 | Non-Final OA | — | Pending | Dec 20, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIrp Health Pty Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Assaf Zilbering has the most, with 1 of Irp Health Pty Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
